Edition:
United States

Neos Therapeutics Inc (NEOS.OQ)

NEOS.OQ on NASDAQ Stock Exchange Global Market

9.95USD
3:59pm EST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$9.95
Open
$10.00
Day's High
$10.15
Day's Low
$9.85
Volume
47,713
Avg. Vol
160,108
52-wk High
$13.15
52-wk Low
$4.85

Latest Key Developments (Source: Significant Developments)

PDL Biopharma urges Neos Therapeutics to provide update on sale process
Wednesday, 8 Nov 2017 08:00am EST 

Nov 8 (Reuters) - PDL Biopharma :PDL Biopharma's proposal to acquire Neos Therapeutics expires today; PDL urges Neos to provide update on sale process.Reiterated that its proposal to acquire Neos Therapeutics Inc for $10.25 per share in cash will expire today at market close​.Decided it will not extend deadline for, or otherwise alter, its proposal​.  Full Article

Neos Therapeutics reports Q3 loss of $0.58/shr
Wednesday, 8 Nov 2017 07:00am EST 

Nov 8 (Reuters) - Neos Therapeutics Inc :Neos Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.58.Q3 earnings per share view $-0.75 -- Thomson Reuters I/B/E/S.Neos Therapeutics Inc - ‍total product revenues were $6.7 million for three months ended September 30, 2017, compared to $1.6 million for same period in 2016​.Q3 earnings per share view $-0.75, revenue view $6.6 million -- Thomson Reuters I/B/E/S.  Full Article

Neos Therapeutics receives paragraph IV certification from Teva Pharmaceuticals USA
Wednesday, 1 Nov 2017 08:11am EDT 

Nov 1 (Reuters) - Neos Therapeutics Inc ::Neos Therapeutics-co received paragraph iv certification from teva pharmaceuticals usa that teva submitted anda for generic version of cotempla xr-odt​.Neos - notice alleges that 3 U.S. Patents in FDA's orange book for cotempla XR-ODT will not be infringed by Teva's generic version of cotempla XR-ODT.Neos - is evaluating paragraph IV certification from Teva Pharmaceuticals USA, intends to "vigorously enforce" ip rights relating to cotempla XR-ODT​.  Full Article

PDL Biopharma issues response to Neos Therapeutics rejection of PDL acquisition proposal
Monday, 30 Oct 2017 04:39pm EDT 

Oct 30 (Reuters) - Pdl Biopharma Inc :PDL Biopharma issues statement in response to Neos Therapeutics rejection of PDL acquisition proposal.PDL Biopharma Inc - ‍PDL's proposal to Neos remains outstanding through November 8, 2017 & co will evaluate "all of its options" in interim​.  Full Article

Neos Therapeutics‍ confirms it got unsolicited proposal from PDL Biopharma
Thursday, 26 Oct 2017 10:02am EDT 

Oct 26 (Reuters) - Neos Therapeutics Inc ::Says confirmed it received unsolicited proposal from PDL Biopharma to buy co for $10.25 per share in cash​.Says Neos board will respond to PDL proposal received on Oct 26 in due course​.  Full Article

PDL BioPharma proposes to acquire Neos Therapeutics for $10.25 per share
Thursday, 26 Oct 2017 08:30am EDT 

Oct 26 (Reuters) - Pdl Biopharma Inc :PDL Biopharma proposes to acquire NEOS THERAPEUTICS for $10.25 per share in cash.PDL Biopharma Inc - ‍PDL proposal is not subject to any financing conditions​.PDL Biopharma Inc - ‍PDL proposal will remain outstanding for a period of fourteen days​.PDL BioPharma Inc - ‍on June 23, 2017, PDL formally proposed to acquire Neos for $10.25 per share, a proposal Neos Board promptly rejected​.PDL BioPharma Inc - ‍reconfirming proposal to purchase Neos Therapeutics for a cash purchase price of $10.25 per share​.PDL BioPharma Inc - ‍following Neos' dilutive financing at $6.25 per share, PDL maintained its $10.25 proposal to Board​.  Full Article

Neos Therapeutics receives U.S. FDA approval
Friday, 15 Sep 2017 04:39pm EDT 

Sept 15 (Reuters) - Neos Therapeutics Inc :Neos Therapeutics receives U.S. FDA approval of Adzenys ER™ (amphetamine) extended-release oral suspension for the treatment of ADHD in patients 6 years and older.Neos Therapeutics Inc - ‍look forward to commercial launch of Adzenys ER in early 2018.  Full Article

Neos Therapeutics Q2 loss per share $0.83
Tuesday, 8 Aug 2017 07:00am EDT 

Aug 8 (Reuters) - Neos Therapeutics Inc ::Neos Therapeutics reports second quarter 2017 financial results.Q2 loss per share $0.83.Q2 earnings per share view $-0.83 -- Thomson Reuters I/B/E/S.Neos Therapeutics Inc - total product revenues were $4.9 million for three months ended June 30, 2017, compared to $1.5 million for same period in 2016..  Full Article

Neos Therapeutics announces proposed offering of common stock
Monday, 26 Jun 2017 04:01pm EDT 

June 26 (Reuters) - Neos Therapeutics Inc -:Neos Therapeutics announces proposed offering of common stock.Neos Therapeutics Inc - has commenced an underwritten public offering of $30 million in shares of its common stock.  Full Article

Neos Therapeutics enters into first amendment to its existing facility agreement with lenders
Monday, 5 Jun 2017 07:32am EDT 

June 5 (Reuters) - Neos Therapeutics Inc -:Neos Therapeutics Inc - ‍on June 1, co, lenders entered into a first amendment to company's existing facility agreement with lenders - sec filing​.Neos Therapeutics - under amendment, date to repay accrued interest under facility agreement was extended to june 1, 2018 which may be extended to June 1, 2019​.Neos Therapeutics - date to repay accrued interest under facility agreement may be extended to June 1, 2019 at election of co if certain conditions have been met.Neos Therapeutics- ‍convertible notes will accrue interest at a rate of 12.95% per annum until maturity date or their earlier repayment or conversion​.  Full Article

BRIEF-Neos Therapeutics reports Q3 loss of $0.58/shr

* Neos Therapeutics reports third quarter 2017 financial results